Academic literature on the topic 'Metronidazol gel vaginal'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Metronidazol gel vaginal.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Metronidazol gel vaginal"
1
Mardikasari, Sandra Aulia, Arfian Junior Amir, Aliyah ., Muhammad Nur Amir, Achmad Himawan, Usmanengsih ., Suci Ananda Putri, Irma Nurfadilla Tuany, and Andi Dian Permana. "DEVELOPMENT OF METRONIDAZOLE MICROSPONGE INCORPORATED INTO CARBOMER-BASED VAGINAL GEL." Journal of Experimental Biology and Agricultural Sciences 9, Spl-2-ICOPMES_2020 (September 8, 2021): S241—S247. http://dx.doi.org/10.18006/2021.9(spl-2-icopmes_2020).s241.s247.
Full textAbstract:
Bacterial vaginosis (BV) is a vaginal infection caused by excessive bacterial growth, thus disrupting the natural balance of bacteria inside the vagina. Metronidazole becomes a drug of choice and a widely prescribed drug for the treatment of BV. However, when applied topically, metronidazole has a low vaginal residence time because of the natural washing mechanism of the vagina. This study aimed to improve the retention time of metronidazole inside the vagina and control its release profile. This study was prepared 4 formulas of gel for metronidazole microsponges with some concentration ratio of carbomer and triethanolamine. The evaluations carried out to test the efficacy of the developed formulation included organoleptic, pH measurement, spreadability, viscosity, mucoadhesive properties, permeation test using Franz diffusion cell and retention test. The results showed that the gel appearance was white, odourless and homogenous. The characteristics of all prepared gel for pH, viscosity, spreadability, and mucoadhesive ability were appropriate to the required standard for vaginal delivery. The permeation and retention test showed that F3 with the carbomer and triethanolamine concentration of 1.25%: 1.75% was able to retain and controlled the drug release locally in the vaginal mucosa. This study provides an alternative strategy in drug formulation for the treatment of BV.
2
Kalita, Banasmita, Kritika Saikia, and Bhupen Kalita. "FORMULATION AND EVALUATION OF METRONIDAZOLE MICROSPHERES-LOADED BIOADHESIVE VAGINAL GEL." Asian Journal of Pharmaceutical and Clinical Research 10, no. 3 (March 1, 2017): 418. http://dx.doi.org/10.22159/ajpcr.2017.v10i3.16417.
Full textAbstract:
ABSTRACTObjectives: The objective of the present work is to develop and characterize metronidazole microsphere-loaded bioadhesive vaginal gel to ensurelonger residence time at the infection site, providing a favorable release profile for the drug.Methods: Microsphere was prepared by solvent evaporation method in various ratios of metronidazole to poly-ε-caprolactone (PCL). Physicochemicalevaluation of microspheres includes determination of solubility in simulated vaginal fluid, partition coefficient (n-octanol/citrate phosphatebuffer pH 4.5), particle size distribution, entrapment efficiency, X-ray diffraction, and surface morphology by scanning electron microscopy (SEM).Drug excipient compatibility was established by Fourier transform infrared and differential scanning calorimetry studies. Bioadhesive gel wasprepared using Carbopol 934P and HPMC K4M in various concentrations, and methyl paraben was used as a preservative. The pH was adjustedwith triethanolamine which resulted in a translucent gel. The optimized metronidazole microsphere formulation was dispersed into the gel base.Microspheres in gel formulations were evaluated for pH, viscosity, spreadability, drug content, and gelling strength. Ex vivo mucoadhesive strength ofthe gel was determined on goat vaginal mucosa. In vitro drug release study was performed using cellophane membrane.Results: The optimized batch of microsphere F4 (drug-polymer ratio 1:4) showed entrapment efficiency of 72.62±3.66%, solubility of 1.5 mg/ml, andpartition coefficient of 0.12. Particle size of all the formulations was observed below 100 μm. Regular and spherical particles were observed in theSEM photomicrographs. The optimized gel formulation G5 (Carbopol and HPMC at 1: 0.25 ratio) showed viscosity of 7538 cps at 100 RPM, gel strengthrecorded as 35 secobds for a 1000.00 mg load, and spreadability of 4.6 g.cm/seconds. G5 showed 82.4% drug release at 10.0 hrs and mucoadhesivestrength of 6.5±1.2 g.Conclusion: The study results suggest that metronidazole-loaded PCL microsphere in mucoadhesive gel would provide a mean for sustainedtreatment of vaginal infections.Keywords: Microsphere, Metronidazole, Bioadhesive vaginal gel.
3
Saleem, Faiqa, Munazza Malik, Muhammad Sohaib Shahid, and Muhammad Tayyab. "BACTERIAL VAGINOSIS;." Professional Medical Journal 24, no. 02 (February 14, 2017): 252–57. http://dx.doi.org/10.29309/tpmj/2017.24.02.520.
Full textAbstract:
In women of reproductive age bacterial vaginosis is a most common polymicrobialdisease and is the leading reason for vaginal discharge in this age group. Additionally itis further linked with sizeable disease burden of community problem in terms of infectiouscomplications. Clindamycin vaginal cream and metronidazole vaginal gel are effective in themanagement of vaginal infections caused by multi bacteria. Objectives: To compare thetherapeutic efficacy of Metronidazole vaginal gel and clindamycin vaginal cream as modality oftreatment for bacterial vaginosis. Study Design: Randomized control trial. Setting: Departmentof Obstetrics and Gynaecology, Unit-3 Jinnah Hospital Lahore. Period: Six months from 02-05-2011 to 01-11-2011. Material & Methods: A total of 300 patients were included in this study.They were divided into two groups. Group A received metronidazole vaginal gel (5 g dailyfor 7 days) while group B administered with clindamycin vaginal cream (5g daily for 7 days).Results: Mean age of the patient was observed 34.3+3.5 and 32.9+ 2.1 years in group –A andB respectively. Vaginal discharge was absent in 104 patients (69.3%) from group A and 127(84.7%) from group-B. Absence of clue cells on microscopy revealed in 112 patients (74.7%)from group A and 137 patients (91.3%) from group B. Absence of amine odour found in 116patients (77.3%) of group A and 134 patients (89.3%) of group B. Significant difference wasfound between two groups with p value of 0.006 in respect of efficacy. Conclusion: Clindamycinvaginal cream is more effective in comparison to Metronidazole vaginal gel for the treatment ofbacterial vaginosis.
4
Wain, A. M. "Metronidazole vaginal gel 0.75% (MetroGel-Vaginal�): A brief review." Infectious Diseases in Obstetrics and Gynecology 6, no. 1 (1998): 3–7. http://dx.doi.org/10.1002/(sici)1098-0997(1998)6:1<3::aid-idog2>3.0.co;2-0.
Full text
5
Schlicht, John R. "Treatment of Bacterial Vaginosis." Annals of Pharmacotherapy 28, no. 4 (April 1994): 483–87. http://dx.doi.org/10.1177/106002809402800412.
Full textAbstract:
OBJECTIVE: The purposeof this articleis to review the treatment options for bacterial vaginosis, including the newer topical antibiotics, metronidazole gel and clindamycin cream. The article also examines the controversies over whether bacterial vaginosis is a sexually transmined disease and whether asymptomatic women should be treated. DATA SOURCE: A MEDLINE search was conducted to identify pertinent literature, including review articles. STUDY SELECTION: Emphasiswas placed on those clinical trials using metronidazole gel or clindamycin cream. Studies addressing the complications of bacterial vaginosis in pregnancy, the risk of treatment in pregnancy, and the method of transmission of the disease also were reviewed. DATA EXTRACTION: Clinical studies evaluating clindamycin cream and metronidazole gel were scarce; therefore, data from all available trials were reviewed. The objectives, methodology, and results from other studies werer eviewed; thoseaddressing complications of the disease and risksand benefits of treatment wereincluded. DATA SYNTHESIS: There is evidence both for and against bacterial vaginosis being a sexually transmined disease. Potential complications of the disease may warrant treatment of certain asymptomatic women, especially during pregnancy. Treatment options include oral or vaginal metronidazole or clindamycin, all of which provide high cure rates. Vaginal antibiotics result in minimal risk to the fetus in pregnant patients. CONCLUSIONS: Complications of bacterial vaginosis maybe associated with significant morbidity, especially among pregnant women. Treatment of asymptomatic women with the disease is controversial, but may be justified in certain high-risk populations. The topical agents, clindamycin vaginal cream 2% and metronidazole vaginal gel 0.75% provide a safe, effective, but expensive alternative to oral antibiotic regimens for the treatment of bacterial vaginosis.
6
Waheed, Afifa, Humera Yasmeen, and Nabeela Shami. "BACTERIAL VAGINOSIS." Professional Medical Journal 22, no. 08 (August 10, 2015): 989–95. http://dx.doi.org/10.29309/tpmj/2015.22.08.1143.
Full textAbstract:
Bacterial vaginosis is the most common vulvovaginal infection and representsthe 35% of all the infections occurring in women in the reproductive age. Serious forms ofcan induce several complications such as spontaneous preterm labour and preterm birth, latemiscarriage and postpartum endometritis, PID, infertility, vaginal cuff infection and postabortalsepsis. Objective: To compare the efficacy of vaginal metronidazole and vaginal clindamycinin the treatment of bacterial vaginosis. Study Design: Interventional: Quasi experimental study.Setting: Obstetrics outpatient department, Ghurki Trust Teaching Hospital, Lahore. Durationof study: Six months i.e. from 01-01-2009 to 30-06-2009. Results: Mean age of patients wasfound to be 24.33 years. In the 100 patients enrolled, no statistically significant difference wasfound between Clindamycin 2% vaginal cream compared with metronidazole 0.75% vaginalgel using Amsell’s criteria. Metronidazole has a failure rate of 13% while failure rate was 6% inthe clindamycin group. Conclusion: A 3 day regimen of clindamycin 2% vaginal cream wasas effective as 5 day regimen of metronidazole 0.75% vaginal gel in the treatment of bacterialvaginosis.
7
Wain, A. M. "Metronidazole Vaginal Gel 0.75% (MetroGel-Vaginal®): A Brief Review." Infectious Diseases in Obstetrics and Gynecology 6, no. 1 (1998): 3–7. http://dx.doi.org/10.1155/s1064744998000027.
Full text
8
Devillard, Estelle, Jeremy P. Burton, and Gregor Reid. "Complexity of Vaginal Microflora as Analyzed by PCR Denaturing Gradient Gel Electrophoresis in a Patient With Recurrent Bacterial Vaginosis." Infectious Diseases in Obstetrics and Gynecology 13, no. 1 (2005): 25–30. http://dx.doi.org/10.1155/2005/607474.
Full textAbstract:
Objective:Gardnerella vaginalishas long been the most common pathogen associated with bacterial vaginosis (BV). We aimed to test our hypothesis that symptoms and signs of BV do not necessarily indicate colonization by this organism, and often will not respond to standard metronidazole or clindamycin treatment.Methods:Using a relatively new molecular tool, PCR denaturing gradient gel electrophoresis (DGGE), the vaginal microflora of a woman with recalcitrant signs and symptoms of BV was investigated over a 6-week timeframe.Results:The vagina was colonized by pathogenic enterobacteriaceae, staphylococci andCandida albicans. The detection of the yeast by PCR-DGGE is particularly novel and enhances the ability of this tool to examine the true nature of the vaginal microflora. The patient had not responded to antifungal treatment, antibiotic therapy targeted at anaerobic Gram-negative pathogens such asGardnerella, nor daily oral probiotic intake ofLactobacillus rhamnosusGG. The failure to find the GG strain in the vagina indicated it did not reach the site, and the low counts of lactobacilli demonstrated that therapy with this probiotic did not appear to influence the vaginal flora.Conclusions:BV is not well understood in terms of its causative organisms, and further studies appear warranted using non-culture, molecular methods. Only when the identities of infecting organisms are confirmed can effective therapy be devized. Such therapy may include the use of probiotic lactobacilli, but only using strains which confer a benefit on the vagina of pre- and postmenopausal women.
9
duBOUCHET, LORRAINE, JAMES A. McGREGOR, MAHMOUD ISMAIL, and WILLIAM M. McCORMACK. "A Pilot Study of Metronidazole Vaginal Gel Versus Oral Metronidazole for the Treatment of Trichomonas vaginalis Vaginitis." Sexually Transmitted Diseases 25, no. 3 (March 1998): 176–79. http://dx.doi.org/10.1097/00007435-199803000-00012.
Full text
10
Han, Sang Won, and Jae Eun Chung. "Comparison of intravaginal and oral metronidazole in patients with bacterial vaginosis." International Journal of Reproduction, Contraception, Obstetrics and Gynecology 6, no. 10 (September 23, 2017): 4213. http://dx.doi.org/10.18203/2320-1770.ijrcog20174396.
Full textAbstract:
Background: Metronidazole is considered an effective treatment for bacterial vaginosis. Only oral preparations were available until 2014, but an intravaginal gel preparation recently became commercially available in South Korea. In this report, the efficacy and safety of metronidazole intravaginal gel application was compared to that of the conventional oral metronidazole preparation.Methods: Patients who were treated with either intravaginal metronidazole or oral metronidazole after diagnosis of bacterial vaginosis were included in this study. Patient characteristics, mode of treatment, recurrence rate, and complications including gastro-intestinal discomfort and concomitant vulvovaginal candidiasis were analyzed.Results: There were no differences in patient characteristics, except the mean age was older in the intravaginal group. Treatment outcomes were similar in both groups. In the oral metronidazole group, 6.3% of patients reported ongoing symptoms of bacterial vaginosis within one month of treatment and required a refill, while 7.3% of the intravaginal group required a refill. Significantly more patients on oral metronidazole treatment complained about gastro-intestinal discomfort including nausea (13.4%) and diarrhea (9.4%). Patients who took intravaginal metronidazole complained about increased watery vaginal discharge (26.8%). The comparatively high cost of metronidazole intravaginal gel was another factor that could affect patient access to this treatment versus the oral preparation. The incidence of vulvovaginal candidiasis was similar between groups (oral 3.9%, intravaginal 4.9%).Conclusions: Intravaginal metronidazole usage can be considered as an effective alternative treatment for bacterial vaginosis in patients with gastro-intestinal complications. However, the increased incidence of watery vaginal discharge and high cost remain obstacles to widespread use of the intravaginal preparation.
Dissertations / Theses on the topic "Metronidazol gel vaginal"
1
LEITE, Sonia Regina Ribeiro de Figueiredo. "Ensaio clínico randomizado comparando dois tratamentos para vaginose bacteriana, com estudo descritivo do perfil clínico, epidemiológico e microbiológico das mulheres antes do tratamento." Universidade Federal de Pernambuco, 2009. https://repositorio.ufpe.br/handle/123456789/6976.
Full textAbstract:
Made available in DSpace on 2014-06-12T18:28:04Z (GMT). No. of bitstreams: 2
arquivo1143_1.pdf: 1341192 bytes, checksum: 28c1a0abdeb803275cd83cc199fae089 (MD5)
license.txt: 1748 bytes, checksum: 8a4605be74aa9ea9d79846c1fba20a33 (MD5)
Previous issue date: 2009INSTITUTO DE MEDICINA INTEGRAL PROF FERNANDO FIGUEIRA
Esta tese, apresentada em dois artigos, teve por objetivo comparar dois tratamentos para Vaginose Bacteriana, utilizando metronidazol e aroeira, em aplicação tópica vaginal e estudar o perfil clínico, epidemiológico e bacteriológico das mulheres participantes, antes de serem submetidas ao tratamento. O primeiro artigo consistiu de um ensaio clínico randomizado, duplamente mascarado, que comparou a eficácia entre os dois tratamentos em mulheres com vaginose bacteriana diagnosticada, concomitantemente, pelos critérios de Amsel e Nugent. Foi utilizada a Análise por Intenção de Tratar. Do total de 277 participantes do ensaio clínico, 137 mulheres foram tratadas com gel de Aroeira e 140 tratadas com Metronidazol. Na avaliação de cura pelos critérios de Amsel, 21,2% das pacientes que utilizaram aroeira e 62,1% que usaram metronidazol obtiveram cura. Quando o Escore de Nugent foi utilizado foram curadas 13,9% das mulheres do grupo da aroeira e 56,4% do grupo metronidazol. A cura total (com a utilização dos dois critérios) foi observada em 12,4% do total de pacientes no grupo da aroeira e 56,4% das mulheres que usaram metronidazol. O segundo artigo constou de uma série de casos onde foram estudados os achados clínicos, epidemiológicos e microbiológicos das participantes do ensaio clínico antes do tratamento, além da presença de lactobacilos nas citologias oncóticas e a população bacteriana componente das microbiotas vaginais identificadas por culturas de secreção vaginal. Entre as queixas clínicas, as mais frequentes foram o corrimento genital, observado em 74,4% das participantes e o odor de peixe da secreção vaginal, que ocorreu em 68,6% dos casos. As culturas de conteúdo vaginal permitiram a identificação de Gardnerella vaginalis em 96,8% e de Mobiluncus em 53,1% dos casos. Apenas em uma terça parte dos exames (32,1%) havia a presença de Lactobacillus. Como conclusões dos estudos, foram observados índices de cura menores com a utilização de Aroeira do que com Metronidazol; os efeitos colaterais foram pouco frequentes e sem maior gravidade em ambos os grupos e continuam necessários novos estudos que melhor elucidem as inter-relações entre os achados microbiológicos e a expressão clínica da doença
Book chapters on the topic "Metronidazol gel vaginal"
1
"Metronidazole Vaginal Gel." In Hale’s Medications & Mothers’ Milk™ 2019. New York, NY: Springer Publishing Company, 2018. http://dx.doi.org/10.1891/9780826150356.0680.
Full text